Wuhan Binhui Biopharmaceutical Co., Ltd
- Biotech or pharma, therapeutic R&D
Seeking to partner Oncolytic HSV2 (OH2) virus a) in phase III for melanoma (US: Fast-Track & Orphan Designation; CN: pre-BLA & Breakthrough Therapy) and b) Colorectal Cancer: US EOP2 in preparation. Both are supported by favorable safety & efficacy trial results from China (>270 pts).
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}